⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VIR News
Vir Biotechnology, Inc. Common Stock
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology USA - English USA - English
prnewswire.com
VIR
ALNY
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
businesswire.com
VIR
Prostate Cancer Drugs Market to Reach USD 28.10 Billion by 2033 | According to DataM Intelligence
prnewswire.com
BIIB
MRK
JNJ
PFE
AZN
BMY
GILD
EXEL
RDVY
CRIS
VRTX
INCY
ABBV
LULU
VIR
FGEN
HALD
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
businesswire.com
VIR
Ability Biotherapeutics Expands its Scientific Advisory Board with the Appointment of Dr. John Burke and Dr. Alan Korman
businesswire.com
BMY
CMRT
VIR
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
businesswire.com
VIR
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
businesswire.com
VIR
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
businesswire.com
VIR
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN ® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
businesswire.com
VIR
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting ® 2025
businesswire.com
VIR